Seals Ambulance sells to Tennessee firm
Seals Ambulance, with 325 workers and nearly $13 million in revenue, will be acquired by Priority Ambulance, but keep its local leadership and name.
Health Care Businesses
Articles
Lilly adds $375M to Zymeworks partnership
Eli Lilly and Co. and Zymeworks said Wednesday that they are expanding a cancer drug development partnership.
Zimmer profit beats forecasts, shares rise 4 percent
Shares of Warsaw-based orthopedic device maker Zimmer Holdings Inc. have doubled the performance of the S&P 500 so far this year.
Eli Lilly to sell Puerto Rico manufacturing facility
The Indianapolis company said it is closing its Guayama facility because the patents on some of the drugs made there have expired.
Lilly partner ordered to pay more than $2M to ex-Actos user
Takeda Pharmaceutical Co. was ordered by a jury to pay more than $2 million to a woman who claimed the company’s Actos diabetes medicine caused her bladder cancer, in the latest of thousands of lawsuits involving the drug to go to trial.
St. Vincent closure of Lafayette hospital to ax 83 jobs
St. Vincent Health will close its long-term acute hospital in Lafayette in the next two months, leaving as many as 83 workers without jobs. St. Vincent will continue to operate its other Seton Specialty Hospital in Indianapolis.
Lilly partner accused of putting Actos profit ahead of safety
Executives knew by 2004 that studies found links between Actos and cancer, and didn’t issue a warning until seven years later to protect billions of dollars in sales of the drug, attorney Michael Miller told a state-court jury in Philadelphia on Thursday.
European regulators OK Lilly’s $5.4B Novartis deal
The European Union's antitrust authority has approved the $5.4 billion sale of Novartis' animal health division to Indianapolis-based pharmaceutical firm Eli Lilly and Co.
Lilly to end development of lupus drug after trial failure
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
IU Health CFO: 3 years to go in difficult transition
In the past two years, IU Health has laid off 935 people, halted construction of a major bed tower, sold off health clinics and decided to close its proton-therapy center. But there are three more years of changes to come, said CFO Ryan Kitchell.
Major Health to put new $89 million hospital along I-74
Major Health Partners will construct the new hospital on the north edge of Shelbyville, after nearly a decade of shifting services to that location. Construction could begin next month.
Testosterone drugs need study on heart risks, FDA panel says
Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.
Community Health plans $175M expansion of East facilities
Community executives said the investment and projects, which will begin this fall and extend over several years, prove their long-term commitment to the east side of the city.
FDA set to review testosterone-boosting drug usage
Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Lilly execs make pitch for local preschool education
Eli Lilly and Co. executives on Friday repeated their plea to local businesses to support early childhood education, highlighting the work force development and crime-reduction benefits associated with the effort.
Lilly cancer drug fares well in late-stage study
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
Lilly receives European marketing OK for new insulin
European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent-infringement litigation with French rival Sanofi.
Lilly says new insulin fares better than rival’s in late-stage tests
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Feds: AIT’s Evans ‘unjustly enriched’ himself in sale to employees
Just three months before the parent company of AIT Laboratories was sold in 2009 to its employees for $90 million, it was appraised for $17.1 million, according to a U.S. Department of Labor lawsuit.